CM vs ITUB

The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial strength. While the company exhibits explosive growth (Earnings +46.6% YoY) and a strong track record of earnings beats, these are countered by a severely bearish technical trend (10/100) and a current price that has already exceeded analyst target prices. The stock trades at a premium to its Graham Number ($89.37) but remains well below its growth-based intrinsic value ($207.09), suggesting a conflict between short-term health risks and long-term growth potential.

ITUB presents a contradictory profile: while it maintains a strong ROE of 21.01% and trades near its intrinsic value of $8.96, its deterministic health is severely compromised with a Piotroski F-Score of 2/9. The stock is currently priced at a slight premium to the Graham Number ($8.18) and above the average analyst target price of $8.36. Despite strong historical 1-year price appreciation (+60.3%), the current technical trend is heavily bearish (10/100), suggesting a potential reversal or consolidation phase. The combination of weak fundamental health scores and a high dividend payout ratio offsets the company's dominant market position.